IShares Biotechnology Financial Statements From 2010 to 2025
| IBB Etf | USD 138.66 0.21 0.15% |
Check IShares Biotechnology financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among IShares Biotechnology's main balance sheet or income statement drivers, such as , as well as many indicators such as . IShares financial statements analysis is a perfect complement when working with IShares Biotechnology Valuation or Volatility modules.
IShares |
iShares Biotechnology ETF ETF Price To Sales Analysis
IShares Biotechnology's Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.
Current IShares Biotechnology Price To Sales | 4.94 X |
Most of IShares Biotechnology's fundamental indicators, such as Price To Sales, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, iShares Biotechnology ETF is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.
| Competition |
IShares Biotechnology Price To Sales Component Assessment
Based on the latest financial disclosure, iShares Biotechnology ETF has a Price To Sales of 4.94 times. This is much higher than that of the iShares family and 86.77% higher than that of the Health category. The price to sales for all United States etfs is notably lower than that of the firm.
iShares Biotechnology ETF Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining IShares Biotechnology's current stock value. Our valuation model uses many indicators to compare IShares Biotechnology value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across IShares Biotechnology competition to find correlations between indicators driving IShares Biotechnology's intrinsic value. More Info.iShares Biotechnology ETF is considered the top ETF in price to earning as compared to similar ETFs. It also is considered the top ETF in price to book as compared to similar ETFs fabricating about 1.07 of Price To Book per Price To Earning. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the IShares Biotechnology's earnings, one of the primary drivers of an investment's value.About IShares Biotechnology Financial Statements
IShares Biotechnology stakeholders use historical fundamental indicators, such as IShares Biotechnology's revenue or net income, to determine how well the company is positioned to perform in the future. Although IShares Biotechnology investors may analyze each financial statement separately, they are all interrelated. For example, changes in IShares Biotechnology's assets and liabilities are reflected in the revenues and expenses on IShares Biotechnology's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in iShares Biotechnology ETF. Please read more on our technical analysis and fundamental analysis pages.
The fund generally will invest at least 80 percent of its assets in the component securities of its index and in investments that have economic characteristics that are substantially identical to the component securities of its index and may invest up to 20 percent of its assets in certain futures, options and swap contracts, cash and cash equivalents. Nasdaq Biotechnology is traded on NASDAQ Exchange in the United States.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether iShares Biotechnology ETF offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of IShares Biotechnology's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Ishares Biotechnology Etf. Outlined below are crucial reports that will aid in making a well-informed decision on Ishares Biotechnology Etf:Check out the analysis of IShares Biotechnology Correlation against competitors. You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
The market value of iShares Biotechnology ETF is measured differently than its book value, which is the value of IShares that is recorded on the company's balance sheet. Investors also form their own opinion of IShares Biotechnology's value that differs from its market value or its book value, called intrinsic value, which is IShares Biotechnology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because IShares Biotechnology's market value can be influenced by many factors that don't directly affect IShares Biotechnology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between IShares Biotechnology's value and its price as these two are different measures arrived at by different means. Investors typically determine if IShares Biotechnology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, IShares Biotechnology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.